СУЧАСНІ ПІДХОДИ ДО ДІАГНОСТИКИ І ЛІКУВАННЯ ХВОРИХ НА РАК МОЛОЧНОЇ ЗАЛОЗИ
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-1-2021-g.9320Ключові слова:
гетерогенність, діагностика, мікроРНК, персоніфіковане лікування, рак молочної залозиАнотація
В огляді проаналізовано сучасну інформацію щодо діагностики та лікування пацієнток з первинно-операбельним раком молочної залози (РМЗ), приділено увагу розвитку персоніфікованих підходів до стратегії терапії цього розповсюдженого захворювання. У статті автори наводять результати клінічних досліджень, у яких підтверджується роль визначення експресії мікроРНК не тільки для своєчасного і повноцінного, але й для індивідуального лікування пацієнток. Виражена гетерогенність РМЗ і виділення підтипів цього захворювання, засноване на клініко-морфологічних, молекулярно-генетичних, епідеміологічних та інших підходах, а також помітні відмінності у факторах ризику дозволяють говорити, що питання щодо лікування хворих на РМЗ остаточно не вирішено. Тим не менш сучасний рівень знань про молекулярні механізми виникнення і розвитку РМЗ, його чутливості або резистентності до різних препаратів і впливів дозволяє розробляти перехід від усереднених стандартних схем терапії до призначення лікування відповідно до індивідуальних особливостей пацієнтки і біологічних характеристик пухлини. Крім того, поглиблення нашого розуміння біології РМЗ могло б бути ключем до розуміння розвитку місцевого рецидиву та віддалених метастазів після радикального лікування.
Посилання
Konat-Bąska K, Matkowski R, Błaszczyk J, et al. Does breast cancer increasingly affect younger women? Int J Environ Res Public Health 2020; 17 (13): 4884 (https://www.mdpi.com/1660–4601/17/13/4884).
Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014; 16 (3): R65 (https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3679).
Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121 (10): 3786–88.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747–52.
Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6 (4): 375–392.
Guidroz JA, Scott-Conner CEH, Weiget RJ. Management of pregnant women with breast cancer. J Surg Oncol 2011; 103 (4): 337–40.
Bullier B, MacGrogan G, Bonnefoi H, et al. Imaging features of sporadic breast cancer in women under 40 years old. Eur Radiol 2013; 23 (12): 3237–45.
Olivas-Maguregui S, Villasenor-Navarro Y, Ferrari-Carballo T, et al. Importance of the preoperative evaluation of multifocal and multicentric breast cancer with magnetic resonance imaging in women with dense parenchyma. Rev Invest Clin 2008; 60 (5): 382–9.
Corradini S, Reitz D, Pazos M, et al. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers 2019; 1 1(2): 160 (https://www.mdpi.com/2072–6694/11/2/160).
Pallone MJ, Poplack SP, Barth RJ, et al. Combining supine MRI and 3D optical scanning for improved surgical planning of breast conserving sugeries. Proceedings of the SPIE 2012; 8316: id. 83163B (DOI: 10.1117/12.912803)
Soares F, Janela F, Pereira M, et al. 3D lacunarity in multifractal analysis of breast tumor lesions in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Image Process 2013; 22(11–12): 4422–35.
Schilling K, Narayanan D, Kalinyak JE, et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imag 2011; 38 (1): 23–6.
Fann JC-Y, Chang K-J, Hsu C-Y, et al. Impact of overdiagnosis on long-term breast cancer survival. Cancers 2019; 11: 325 (https://www.mdpi.com/2072–6694/11/3/325).
Ogbuanya AU, Anyanwu SN, Iyare EF, et al. The role of fine needle aspiration cytology in triple assessment of patients with malignant breast lumps. Niger J Surg 2020; 26 (1): 35–41.
Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23 (30): 7721–35.
Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25 (30): 4772–78.
Gonçalves A, Sabatier R, Charafe-Jauffret E, et al. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer 2013; 100 (5): 453–64.
Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007; 102 (1): 43–9.
Creighton CJ, Kent Osborne C, van de Vijver MJ, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287–99.
Bose S. Triple-negative breast carcinoma: morphologic and molecular subtypes. Аdv Anat Pathol 2015; 22 (5): 306–13.
Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012; 131 (11): 2471–77.
Wang J, Zhang K-Y, Liu S-M, et al. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 2014; 19 (2): 1912–38.
Iwakawa H-O, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends in Cell Biol 2015; 25 (11): 651–65.
John B, Enright AJ, Aravin A, et al. Human microRNA targets. PLoS Biol 2004; 2 (11): e363.
Rajewsky N. microRNA target predictions in animals. Nat Genet 2006; 38(6): S8–S13.
Friedman RC. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19 (1): 92–105.
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834–38.
Zaravinos A. The regulatory role of microRNAs in EMT and cancer. J Oncol 2015; 2015: 865816.
Eissa S, Matboli M, Shehata HH, et al. MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer. Tumor Biol 2015; 36 (6): 4487–94.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449 (7163): 682–88.
Abdulhussain MM, Hasan NA, Hussain AG. Interrelation of the circulating and tissue MicroRNA-21 with tissue PDCD4 expression and the invasiveness of Iraqi female breast tumors. Indian J Clin Biochem 2019; 34 (1): 26–38.
Zheng SR, Guo GL, Zhai Q, et al. Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac J Cancer Prev 2013; 14 (4): 2361–66.
Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013; 20 (1): 1–10.
Yu SJ, Hu JY, Kuang XY, et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 2013; 19 (6): 1389–99.
Wang Y, Rathinam R, Walch A, et al. ST14 (Suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 2009; 284 (34): 23094–106.
Zhang L, Du Y, Xu S, et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Lett 2019; 442: 242–51.
Li J, Li X, Kong X, et al. MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med 2014; 7 (3): 558–65.
Ma X, Dong W, Su Z, et al. Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4. Cell Death Dis 2016; 7 (12): e2561–e2561.
Yan G, Li Y, Zhan L, et al. Decreased miR-124–3p promoted breast cancer proliferation and metastasis by targeting MGAT5. Am J Cancer Res 2019; 9 (3): 585–96.
Seo S, Moon Y, Choi J, et al. The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205. Am J Cancer Res 2019; 9 (3): 597–607.
Wang L, Kang FB, Wang J, et al. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway. Anti-Cancer Drugs 2019; 30 (3): 225–32.
Lo TF, Tsai WC, Chen ST. MicroRNA-21–3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One 2013; 8 (9): e75628.
Lo SN, Wang CW, Chen YS, et al. Berberine activates aryl hydrocarbon receptor but suppresses CYP1A1 induction through miR-21–3p stimulation in MCF-7 breast cancer cells. Molecules 2017; 22 (11): 1847 (https://www.mdpi.com/1420–3049/22/11/1847).
Lin C, Gao B, Yan X, et al. MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1. Onco Targets Ther 2018; 11: 5419–28.
Khalighfard S. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep 2018; 8 (1): 1–11.
Shi J. Considering exosomal miR-21 as a biomarker for cancer. J Clin Med 2016; 5 (4): 42 (https://www.mdpi.com/2077–0383/5/4/42).
Eichelser C, Stückrath I, Müller V, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 2014; 5 (20): 9650–63.
Fortis SP, Vaxevanis CK, Mahaira LG, et al. Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics. Cancer Immunol Immunother 2019; 68 (1): 57–70.
Mishra S, Srivastava AK, Suman S, et al. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett 2015; 369 (1): 67–75.
Masuda T, Shinden Y, Noda M, et al. Circulating pre-microRNA-488 in peripheral blood is a potential biomarker for predicting recurrence in breast cancer. Anticancer Res 2018; 38 (8): 4515–23.
Liu B, Su F, Chen M, et al. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Human Pathol 2017; 64: 44–52.
Dooley WC. Surgery for breast cancer. Curr Opin Oncol 1998; 10 (6): 504–12.
Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 2015; 12 (2): 115–24.
Cattelani L, Polotto S, Arcuri MF, et al. One-step prepectoral breast reconstruction with dermal matrix-covered implant compared to submuscular implantation: functional and cost evaluation. Clin Breast Cancer 2018; 18 (4): e703–e711.
Riis M. Modern surgical treatment of breast cancer. Ann Med Surg (Lond) 2020; 56: 95–107.
Tosello G, Torloni MR, Mota BS, et al. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 2018; 3 (3): CD011276 (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011276.pub2/full).
Cheung KL. Treatment strategies and survival outcomes in breast cancer. Cancers (Basel) 2020; 12 (3): 735 (https://www.mdpi.com/2072–6694/12/3/735/htm).
Salibian AA, Frey JD, Karp NS. Strategies and considerations in selecting between subpectoral and prepectoral breast reconstruction. Gland Surg 2019; 8 (1): 11–18.
Brown M, Namnoum JD. Indications and controversies for implant-only based breast reconstruction. Clin Plast Surg 2018; 45 (1): 47–54.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019; 321 (3): 288–300.
Moo TA, Sanford R, Dang C, et al. Overview of breast cancer therapy. PET Clin 2018; 13 (3): 339–54.
Weber WP, Soysal SD, El-Tamer M, et al. First international consensus conference on standardization of oncoplastic breast conserving surgery. Breast Cancer Res Treat 2017; 165 (1): 139–49.
Rubio IT, Wyld L, Esgueva A, et al. Variability in breast cancer surgery training across Europe: an ESSO-EUSOMA international survey. Eur J Surg Oncol 2019; 45 (4): 567–72.
Nounou MI, El Amrawy F, Ahmed N, et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 2015; 9 (Suppl 2): 17–34.
Murphy BD, Kerrebijn I, Farhadi J, et al. Indications and controversies for abdominally-based complete autologous tissue breast reconstruction. Clin Plast Surg 2018; 45 (1): 83–91.
Walker DK, Whitehead L. Breast surgery for metastatic breast cancer. Br J Community Nurs 2018; 23 (7): 334–35.
Lanitis S, Tekkis PP, Sgourakis G, et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg 2010; 251 (4): 632–39.
De La Cruz L, Moody AM, Tappy EE, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol 2015; 22 (10): 3241–49.
Lewis L, Cox J, Morgia M, et al. A clip-based protocol for breast boost radiotherapy provides clear target visualisation and demonstrates significant volume reduction over time. J Med Radiat Sci 2015; 62: 177–83.
Winzer KJ, Sauerbrei W, Braun M, et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010; 46 (1): 95–101.
Hlavka A, Vanasek J, Odrazka K, et al. Tumor bed radiotherapy in women following breast conserving surgery for breast cancer-safety margin with/without image guidance. Oncol Lett 2018; 15: 6009–14.
Matuschek C, Bölke E, Haussmann J, et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol 2017; 12 (1): 60 (https://ro-journal.biomedcentral.com/articles/10.1186/s13014–017–0796-x).
Onitilo AA, Engel JM, Stankowski RV, et al. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res 2015; 13: 65–73.
Land LH, Dalton SO, Jensen MB, et al. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 2012; 107 (11): 1901–07.
Tann AW, Hatch SS, Joyner MM, et al. Accelerated partial breast irradiation: Past, present, and future. World J Clin Oncol 2016; 7 (5): 370–9.
Koerkamp GML, Vasmel JE, Russell NS, et al. Optimizing MR-guided radiotherapy for breast cancer patients. Front Oncol 2020; 10: 1107 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399349/).
Lalani N, Voduc KD, Jimenez RB, et al. Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity. Int J Radiat Oncol Biol Phys 2021; 109 (1): 281–7.
Kayali M, Abi Jaoude J, Tfayli A, et al. Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all. Crit Rev Oncol Hematol 2020; 147: 102880 (https://www.sciencedirect.com/science/article/abs/pii/S1040842820300184).
Bergh J, Jönsson PE, Glimelius B, et al. Swedish council of technology assessment in health care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40 (2–3): 253–81.
Hussain SA, Palmer DH, Stevens A, et al. Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther 2005; 5 (6): 1095–110.
Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci 2005; 60 (9): 1137–44.
Hassan MS, Ansari J, Spooner D, et al. Chemotherapy for breast cancer (Review). Oncol Rep 2010; 24 (5): 1121–31.
Swain SM. Chemotherapy: updates and new perspectives. Oncologist 2011; 16 (Suppl 1): 30–39.
Hennigs A, Riedel F, Marmé F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 2016; 160(3): 491–99.
Zarcos-Pedrinaci I, Redondo M, Louro J, et al. Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Med 2019; 8 (15): 6662–70.
Cheung KL. Treatment strategies and survival outcomes in breast cancer. Cancers (Basel) 2020; 12 (3): 735 (https://www.mdpi.com/2072–6694/12/3/735/htm).
Haidinger R, Bauerfeind I. Long-term side effects of adjuvant therapy in primary breast cancer patients: results of a web-based survey. Breast Care (Basel) 2019; 14 (2): 111–16.
El Hachem G, Gombos A, Awada A. Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Res 2019; 8: F1000 Faculty Rev-591.
Mehanna J, Haddad FG, Eid R, et al. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 2019; 11: 431–37.
Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv 2020; 2020: 1–11.
Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol 2020; 47 (4): 187–200.
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 2012; 8: e149–57.
Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011; 104: 1762–69.
Goldhirsch A, Wood WC, Coates AS. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy for early breast cancer. Ann Oncol 2011; 22: 1736–47.
Abdulkareem IH, Zurmi IB. Review of hormonal treatment of breast cancer. Niger J Clin Pract 2012; 15 (1): 9–14.
Thurlimann B, Price KN, Gelber RD. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11–93. Breast Cancer Res Treat 2009; 113: 137–44.
Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011; 62; 281–293.
Dembinski R, Prasath V, Bohnak C, et al. Estrogen receptor positive and progesterone receptor negative breast cancer: the role of hormone therapy. Horm Cancer 2020; 11 (3–4):148–154.
Rauh C, Schuetz F, Rack B, et al. Hormone therapy and its effect on the prognosis in breast cancer patients. Geburtshilfe Frauenheilkd 2015; 75 (6): 588–96.
Drăgănescu M, Carmocan C. Hormone Therapy in breast cancer. Chirurgia (Bucur) 2017; 112 (4): 413–17.
Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol 2012; 6 (2): 222–36.
Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. Curr Oncol 2018; 25 (4): 285–91.
Shen LS, Jin XY, Wang XM, et al. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chin Med J (Engl) 2020; 133 (9): 1099–08.
Kreutzfeldt J, Rozeboom B, Dey N, et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res 2020; 10 (4): 1045–67.
Mazzotta M, Krasniqi E, Barchiesi G, et al. Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med 2019; 8 (2): 254 (https://www.mdpi.com/2077–0383/8/2/254).
Maximiano S, Magalhães P, Guerreiro MP, et al. Trastuzumab in the Treatment of Breast Cancer. BioDrugs 2016; 30 (2): 75–86.
Pinto AC, Ades F, de Azambuja E, et al. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 2013; 22 (Suppl 2): S152–5.
González-Santiago S, Saura C, Ciruelos E, et al. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat 2020; 184 (2): 469–479.
Zagouri F, Sergentanis TN, Chrysikos D, et al. Pertuzumab in breast cancer: a systematic review. Clin Breast Cancer 2013; 13 (5): 315–24.
Tookman L, Roylance R. New drugs for breast cancer. Brit Med Bull 2010; 96: 111–29.
Wilson FR, Coombes ME, Wylie Q, et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst Rev 2017; 6 (1): 196 (https://link.springer.com/article/10.1186/s13643–017–0588–2).
Martin AP, Downing J, Cochrane M, et al. Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Crit Rev Oncol Hematol 2018; 130: 92–107.
Xie Y, Ge R, Sang D, et al. Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: a multicenter, retrospective study. Cancer Med 2020; 9 (9): 2981–88.
Ye X, Luo X, Du Q, et al. Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study. Ann Transl Med 2020; 8(5): 240 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154472/).
Du L, Li X, Zhen L, et al. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep 2018; 17 (5): 7163–69.
Raphael J, Lefebvre C, Allan A, et al. everolimus in advanced breast cancer: a systematic review and meta-analysis. Target Oncol 2020; 15 (6): 723–32.
Sharma M, Duan Z, Zhao H, et al. Real-world patterns of everolimus use in patients with metastatic breast cancer. Oncologist 2020; 25 (11): 937–42.
Krug D, Baumann R, Budach W, et al. Current controversies in radiotherapy for breast cancer. Radiat Oncol 2017; 12 (1): 25 (https://link.springer.com/article/10.1186/s13014–017–0766–3).
Harashchenko O, Antonov V, Konovalenko V. Support tool for decision making in selecting chemotherapy tactics for trearment of breast cancer parients. G Med News. 2019; 6 (291): 20–25.
Manoj Gowda S, Kabeer KK, Jafferbhoy S, et al. Breast cancer management guidelines during COVID-19 pandemic. Indian J Surg 2020; 1–8.
Tasoulis MK, Roche N, MacNeill F. Rationalizing breast cancer surgery during the COVID-19 pandemic. Eur J Surg Oncol 2020; 46 (6): 1192–93.
